NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD
Publication
, Conference
DePaoli, A; Shankar, S; Bashir, MR; Baxter, BA; Van, P; Yan, AZ; Rossi, S
Published in: HEPATOLOGY
December 1, 2018
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2018
Volume
68
Issue
6
Start / End Page
1460A / 1460A
Location
Washington, DC
Publisher
WILEY
Conference Name
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
DePaoli, A., Shankar, S., Bashir, M. R., Baxter, B. A., Van, P., Yan, A. Z., & Rossi, S. (2018). NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD. In HEPATOLOGY (Vol. 68, pp. 1460A-1460A). Washington, DC: WILEY.
DePaoli, Alex, Sudha Shankar, Mustafa R. Bashir, Bryan A. Baxter, Phung Van, Andrew Z. Yan, and Stephen Rossi. “NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD.” In HEPATOLOGY, 68:1460A-1460A. WILEY, 2018.
DePaoli A, Shankar S, Bashir MR, Baxter BA, Van P, Yan AZ, et al. NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD. In: HEPATOLOGY. WILEY; 2018. p. 1460A-1460A.
DePaoli, Alex, et al. “NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD.” HEPATOLOGY, vol. 68, no. 6, WILEY, 2018, pp. 1460A-1460A.
DePaoli A, Shankar S, Bashir MR, Baxter BA, Van P, Yan AZ, Rossi S. NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD. HEPATOLOGY. WILEY; 2018. p. 1460A-1460A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
December 1, 2018
Volume
68
Issue
6
Start / End Page
1460A / 1460A
Location
Washington, DC
Publisher
WILEY
Conference Name
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics